Ibio Inc (NYSEAMERICAN:IBIO) Can’t Be Less Risky. Short Interest Decreased


The stock of Ibio Inc (NYSEAMERICAN:IBIO) registered a decrease of 25.45% in short interest. IBIO’s total short interest was 173,100 shares in September as published by FINRA. Its down 25.45% from 232,200 shares, reported previously. With 43,300 shares average volume, it will take short sellers 4 days to cover their IBIO’s short positions. The short interest to Ibio Inc’s float is 0.96%.

The stock decreased 1.65% or $0.0106 during the last trading session, reaching $0.6316. About 70,463 shares traded. iBio, Inc. (NYSEAMERICAN:IBIO) has declined 18.23% since September 13, 2018 and is downtrending. It has underperformed by 18.23% the S&P500.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. The company has market cap of $15.26 million. The Company’s lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It currently has negative earnings. It is also developing vaccine candidates for third parties.

More notable recent iBio, Inc. (NYSEAMERICAN:IBIO) news were published by: Finance.Yahoo.com which released: “iBio Launches New Sterile Fill-Finish Services – Yahoo Finance” on June 03, 2019, also Globenewswire.com with their article: “iBio, Inc. Prices $16,000,000 Public Offering NYSE:IBIO – GlobeNewswire” published on June 22, 2018, Finance.Yahoo.com published: “iBio and CC-Pharming Expand Business Collaboration in China – Yahoo Finance” on August 26, 2019. More interesting news about iBio, Inc. (NYSEAMERICAN:IBIO) were released by: Finance.Yahoo.com and their article: “iBio Inks 3D Bioprinting Agreement – Yahoo Finance” published on August 19, 2019 as well as Globenewswire.com‘s news article titled: “iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting – GlobeNewswire” with publication date: December 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.